{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "exchange": "FRA", "shortName": "ONCOPEPTIDES AB O.N.", "longName": "Oncopeptides AB (publ)", "messageBoardId": "finmb_12930666", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "regularMarketChangePercent": 2.2370791, "regularMarketPrice": 0.7038, "marketState": "REGULAR", "firstTradeDateMilliseconds": 1487833200000, "priceHint": 4, "epsTrailingTwelveMonths": -0.36, "sharesOutstanding": 90368704, "bookValue": 1.075, "fiftyDayAverage": 0.906052, "fiftyDayAverageChange": -0.20225197, "fiftyDayAverageChangePercent": -0.22322336, "twoHundredDayAverage": 1.50863, "twoHundredDayAverageChange": -0.80483, "twoHundredDayAverageChangePercent": -0.53348404, "marketCap": 65677560, "priceToBook": 0.65469766, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "regularMarketChange": 0.015400052, "regularMarketTime": 1683900901, "regularMarketDayHigh": 0.7112, "regularMarketDayRange": "0.6742 - 0.7112", "regularMarketDayLow": 0.6742, "regularMarketVolume": 500, "regularMarketPreviousClose": 0.6884, "bid": 0.7076, "ask": 0.7356, "bidSize": 0, "askSize": 0, "fullExchangeName": "Frankfurt", "financialCurrency": "SEK", "regularMarketOpen": 0.6914, "averageDailyVolume3Month": 76, "averageDailyVolume10Day": 150, "fiftyTwoWeekLowChange": 0.029600024, "fiftyTwoWeekLowChangePercent": 0.04390392, "fiftyTwoWeekRange": "0.6742 - 4.58", "fiftyTwoWeekHighChange": -3.8762, "fiftyTwoWeekHighChangePercent": -0.8463319, "fiftyTwoWeekLow": 0.6742, "fiftyTwoWeekHigh": 4.58, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "symbol": "OND.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Vastra Tradgardsgatan 15", "city": "Stockholm", "zip": "111 53", "country": "Sweden", "phone": "46 86 15 20 40", "website": "https://www.oncopeptides.com/sv", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Oncopeptides AB (publ), a biotech company, engages in the commercialization, and research and development of treatments for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is melflufen, a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden", "fullTimeEmployees": 41, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jakob  Lindberg Med. Lic", "age": 50, "title": "Chief Scientific Officer", "yearBorn": 1972, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Monica  Shaw M.D.", "age": 43, "title": "Chief Exec. Officer", "yearBorn": 1979, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Prof. Rolf  Larsson M.D., Ph.D.", "title": "Founder", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Prof. Rolf  Lewensohn M.D., Ph.D.", "title": "Founder", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Joachim  Gullbo M.D., MSc Pharm, Ph.D.", "title": "Founder", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Kristina  Luthman Ph.D.", "title": "Founder", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Prof. Hans  Ehrsson M.D.", "title": "Founder", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Peter  Nygren", "age": 63, "title": "Founder", "yearBorn": 1959, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Holger  Lembrer M.Sc.", "age": 38, "title": "Chief Financial Officer", "yearBorn": 1984, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Eva  Nordstr\u00f6m M.Sc., MSc Pharm", "age": 52, "title": "COO & Deputy MD", "yearBorn": 1970, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "maxAge": 86400}}], "error": null}}